On April 2, 2026, discussions between the Trump administration and smaller drug manufacturers are underway to establish new pricing agreements.
These negotiations are reportedly being influenced by the potential imposition of tariffs, which may affect pricing strategies across the sector.
The meetings are taking place at the White House, indicating a direct engagement with smaller players in the pharmaceutical market.